Conditions: Pulmonary Arterial Hypertension
Keywords: Pulmonary Arterial Hypertension PAH WHO Group 1
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 32
Healthy volunteers: no

Brief summary:
The primary objective of this study is to assess the safety and tolerance of changing patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.

Detailed description:
The therapy of pulmonary arterial hypertension (PAH) has been revolutionized with the development and subsequent instruction of oral endothelin receptor antagonists (ERA). The first approved ERA, bosentan (Tracleer, Actelion, Inc.) is an effective drug widely used throughout the world in the therapy of PAH. Newer ERA's, with purported advantages over the first approved drug have since been tested and subsequently been approved for the therapy of PAH in the USA and other countries including ambrisentan (Letairis, Gilead Sciences, Inc.). However, there is little data available on the efficacy, safety and tolerability of the elective change from oral bosentan to oral ambrisentan in PAH.

Arms:
arm 1: patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.

Interventions: intervention 1: ambrisentan
Intervention descriptions: intervention 1: ambrisentan 2.5mg, 5mg, \& 10mg. Daily dosage.

Protocol document: